Warsaw, Poland

Osman Achmatowicz

This inventor holds 1 USPTO granted patent. Top assignee: Instytut Farmaceutyczny. Active years: 2011.


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Osman Achmatowicz: Innovator in Pharmaceutical Chemistry

Introduction

Osman Achmatowicz is a notable inventor based in Warsaw, Poland. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative processes in drug preparation. His work has implications for the development of biologically active substances.

Latest Patents

Achmatowicz holds a patent for a process for the preparation of 13,14-dihydro-PGF2 alpha derivatives. This invention relates to a method for creating 13,14-dihydro-PGF derivatives of R or S configuration at carbon 15, represented by a specific general formula. The compounds produced through this process are valuable biologically active substances or intermediates in their preparation. Notably, the invention focuses on the preparation of 13,14-dihydro-15(R)-17-substituted-18,19,20-trinor-PGF, commonly known as latanoprost.

Career Highlights

Osman Achmatowicz is affiliated with the Instytut Farmaceutyczny, where he has been instrumental in advancing pharmaceutical research. His expertise in the preparation of complex chemical compounds has positioned him as a key figure in his field.

Collaborations

Achmatowicz has collaborated with several professionals, including Jacek Martynow and Julita Szyc. These partnerships have contributed to the successful development of innovative pharmaceutical processes.

Conclusion

Osman Achmatowicz's contributions to pharmaceutical chemistry, particularly through his patented processes, highlight his role as an influential inventor. His work continues to impact the development of important biologically active substances.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…